Quantitation of Insulin-Like Growth Factor 1 in Serum by Liquid Chromatography High Resolution Accurate-Mass Mass Spectrometry

  • Hemamalini Ketha
  • Ravinder J. SinghEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1378)


Insulin-like growth factor 1 (IGF-1) is a 70 amino acid peptide hormone which acts as the principal mediator of the effects of growth hormone (GH). Due to a wide variability in circulating concentration of GH, IGF-1 quantitation is the first step in the diagnosis of GH excess or deficiency. Majority (>95 %) of IGF-1 circulates as a ternary complex along with its principle binding protein insulin-like growth factor 1 binding protein 3 (IGFBP-3) and acid labile subunit. The assay design approach for IGF-1 quantitation has to include a step to dissociate IGF-1 from its ternary complex. Several commercial assays employ a buffer containing acidified ethanol to achieve this. Despite several modifications, commercially available immunoassays have been shown to have challenges with interference from IGFBP-3. Additionally, inter-method comparison between IGF-1 immunoassays has been shown to be suboptimal. Mass spectrometry has been utilized for quantitation of IGF-1. In this chapter a liquid chromatography high resolution accurate-mass mass spectrometry (LC-HRAMS) based method for IGF-1 quantitation has been described.

Key words

High resolution mass spectrometry Insulin-like growth factor-1 quantitation Protein quantitation using mass spectrometry 


  1. 1.
    Laron Z (2001) Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol 54:311–316PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E et al (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058CrossRefPubMedGoogle Scholar
  3. 3.
    Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M et al (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 31:820–838CrossRefPubMedGoogle Scholar
  4. 4.
    Furlanetto RW, Underwood LE, Van Wyk JJ, D’Ercole AJ (1977) Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 60:648–657PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays—a 2009 update. Growth Horm IGF Res 20:8–18CrossRefPubMedGoogle Scholar
  6. 6.
    Clemmons DR (2007) IGF-I assays: current assay methodologies and their limitations. Pituitary 10:121–128CrossRefPubMedGoogle Scholar
  7. 7.
    Breier BH, Gallaher BW, Gluckman PD (1991) Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128:347–357CrossRefPubMedGoogle Scholar
  8. 8.
    Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, Volzke H, Nauck M (2008) Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 46:1776–1783CrossRefPubMedGoogle Scholar
  9. 9.
    Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, Diamandis EP, Lopez MF et al (2013) Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 8:e81125PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Kay RG, Barton C, Velloso CP, Brown PR, Bartlett C, Blazevich AJ, Godfrey RJ, Goldspink G, Rees R, Ball GR et al (2009) High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun Mass Spectrom 23:3173–3182CrossRefPubMedGoogle Scholar
  11. 11.
    Barton C, Kay RG, Gentzer W, Vitzthum F, Pleasance S (2010) Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J Proteome Res 9:333–340CrossRefPubMedGoogle Scholar
  12. 12.
    Bystrom CE, Sheng S, Clarke NJ (2011) Narrow mass extraction of time-of-flight data for quantitative analysis of proteins: determination of insulin-like growth factor-1. Anal Chem 83:9005–9010CrossRefPubMedGoogle Scholar
  13. 13.
    Whiteaker JR, Zhao L, Abbatiello SE, Burgess M, Kuhn E, Lin C, Pope ME, Razavi M, Anderson NL, Pearson TW et al (2011) Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol Cell Proteomics 10(M110):005645PubMedGoogle Scholar
  14. 14.
    Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, Reitz R (2012) Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One 7:e43457PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Departement of PathologyUniversity of Michigan Health SystemAnn ArborUSA
  2. 2.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA

Personalised recommendations